跳至主要内容
临床试验/NL-OMON52100
NL-OMON52100已完成不适用

Real-world exploratory evaluation of the potential drug-drug interaction between anticancer small molecule inhibitors and direct oral anticoagulants in patients with solid tumours, and exploration of the role of therapeutic drug monitoring - Exploratory drug interaction study between SMIs and DOACs

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Treatment of a solid tumour with a SMI
  • 18 years of age or older
  • Already receive or start treatment with a SMI-DOAC combination that may cause a
  • potential clinically significant DDI at the level of CYP3A4 and/or P-gp
  • Combined use of a DOAC-SMI combination is expected to be continued at the same
  • dose for at least three weeks from start of the combined intake
  • DOAC is used for at least 7 days and SMI for at least 21 days before the first
  • blood sampling

排除标准

  • Any concurrent medication besides the SMI and DOAC that is known to strongly
  • inhibit or induce CYP3A4 or P-gp
  • Patients who are pregnant or lactating

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验

Real-world exploratory evaluation of the potential... | 临床试验